Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972409 | 0.97 | DGKA (0.41) | DGKAALOX12EPHX2PSMB8PSMB5 | |
| SCHEMBL17637586 | 0.95 | DGKA (0.43) | DGKAALOX12EPHX2PSMB8PSMB5 | |
| SCHEMBL7954092 | 0.95 | DGKA (0.40) | DGKAALOX12PSMB8PSMB5TDP1 | |
| SCHEMBL16368769 | 0.94 | DGKA (0.33) | DGKAALOX12EPHX2PSMB8PSMB5 | |
| SCHEMBL12285169 | 0.94 | EPHX2 (0.38) | DGKAALOX12EPHX2PSMB8PSMB5 | |
| SCHEMBL126873 | 0.93 | ADRA2A (0.33) | DGKAALOX12PSMB8PSMB5TDP1 | |
| SCHEMBL13041856 | 0.93 | ADRA2A (0.33) | DGKAALOX12PSMB8PSMB5TDP1 | |
| SCHEMBL12285234 | 0.93 | SMN1; SMN2 (0.39) | DGKAALOX12EPHX2PSMB8PSMB5 | |
| SCHEMBL17928351 | 0.92 | DGKA (0.32) | DGKA | |
| SCHEMBL25956279 | 0.92 | DGKA (0.32) | DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | ASCENDIS PHARMA A/S (DK) | 2021-04-20 | — | — | US | disclosed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | disclosed |
| EP-3782649-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2021-02-24 | — | — | EP | disclosed |
| EP-2906245-B1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ASCENDIS PHARMA AS (DK) | 2021-01-13 | — | — | EP | disclosed |
| EP-2459220-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2020-09-09 | — | — | EP | disclosed |
| US-10653795-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| US-20130035635-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA A/S (DK) | 2013-02-07 | — | — | US | disclosed |
| US-20130030359-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR AROMATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-01-31 | — | — | US | disclosed |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | DAO, DNPEP, DDC | DGKA 2693/4885ALOX12 2523/4885EPHX2 378/4885 |
| US-20130030359-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR AROMATIC AMINE-CONTAINING DRUGS | DNPEP, DDC, PEPD | DGKA 2710/4885ALOX12 4515/4885EPHX2 1067/4885 |
| US-20130035635-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | CTSL, SLC16A7, SLC16A8 | DGKA 1426/4885ALOX12 3310/4885EPHX2 928/4885 |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | DGKA 1014/4885ALOX12 2539/4885EPHX2 126/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | DGKA 1014/4885ALOX12 2539/4885EPHX2 126/4885 |
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, LIG3, PLOD2 | DGKA 2661/4885ALOX12 2153/4885EPHX2 168/4885 |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, PLOD2, PLOD1 | DGKA 3230/4885ALOX12 2752/4885EPHX2 301/4885 |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | TNF, ADAMTS5, ADAMTS1 | DGKA 3426/4885ALOX12 862/4885EPHX2 165/4885 |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | IAPP, INSR, GPR119 | DGKA 1347/4885ALOX12 4060/4885EPHX2 4394/4885 |
| US-10653795-B2 | — | PTMS, MSN, CD44 | DGKA 2739/4885ALOX12 3705/4885EPHX2 28/4885 |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | PRAP1, LPXN, DNPEP | DGKA 3211/4885ALOX12 1560/4885EPHX2 533/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | DGKA 1014/4885ALOX12 2539/4885EPHX2 126/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | DGKA 2826/4885ALOX12 4074/4885EPHX2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.